Study Results. 7.1 Upon completion of the Requested Economic Planning Study, the NYISO will deliver the final written report of the completed Requested Economic Planning Study to Requestor, and, upon Requestor’s request, the Parties will meet at a mutually agreeable time and place to review the results of the Requested Economic Planning Study.
7.2 The NYISO will review the results of the Requested Economic Planning Studies to determine whether the results reveal Confidential Information that is not subject to disclosure under the NYISO’s Code of Conduct. Confidential Information will be removed or the results aggregated or masked sufficiently to avoid the disclosure of Confidential Information. The NYISO will post the results of the Requested Economic Planning Study on its website if and when it is required to do so in accordance with Section 31.3.3.10 of Attachment Y to the OATT.
Study Results. After analysis of Study Data from all sites is complete, CRO or Pfizer will provide Principal Investigator with a summary of the overall results of the Study. CRO and Pfizer encourage Principal Investigator to communicate the results, as appropriate, to the Study Subjects. If within two years after Study completion Pfizer identifies results that could affect Study Subject safety, CRO or Pfizer, in consultation with SUKL/the IRB/IEC as appropriate, will cooperate with Principal Investigator or Institution to ensure that those results are appropriately communicated to the Study Subjects by Principal Investigator or Institution.
Study Results. For purposes of clarity (a) the Parties hereby acknowledge and agree, in accordance with Section 1.77, that (1) all data and information obtained or produced in the conduct of the Feasibility Study and/or the Target Confirmation Study (the “Study Results”) shall be jointly owned by the Parties and (2) subject to subsection (b) below, neither Party shall cause or allow any Study Results to be published without the prior written consent of the other Party; and (b) notwithstanding anything to the contrary in Section 10.4, Section 1.77 or subsection (D)(a) above, on and after the date on which [***] becomes a Waived Target pursuant to this Agreement, (1) DICERNA shall solely own the Study Results and have the sole right to use such Study Results for any and all purposes, inside or outside of this Agreement, without restriction, (2) DICERNA shall be deemed to have granted KHK the right to use such Study Results solely for internal research purposes and (3) as between the Parties, DICERNA shall have the sole right to publish such Study Results; provided, that, (i) any contribution of KHK to the Study Results shall be duly recognized and co-authorship shall be determined in accordance with customary industry standards and (ii) to the extent that any such Study Results to be published contain any Confidential Information of KHK, including without limitation KHK [***] DDS Technology or KHK Program Technology, DICERNA shall obtain the prior written consent of KHK to such publication.
Study Results. Following the Subscription Closing Date, the Corporation shall provide to the Investor a draft of any press release announcing the results of the Study, and shall consider, acting reasonably, any comments made by the Investor thereon; provided, however, that the Corporation shall not be required to provide such opportunity to comment in the event that, in the opinion of its outside legal counsel, the Corporation is required to make immediate disclosure of such results under Securities Laws. The foregoing right of the Investor shall terminate upon the earlier of: (a) the Investor’s Ownership Percentage falling below 5.0%; and (b) the later of (i) the date that is 18 months following the Subscription Closing Date and (ii) 6 months following completion of the Study; provided, however, that the Corporation and the Investor may mutually agree to extend the time periods referred to in (b) above by such additional period of time as may be agreed in writing between the Corporation and the Investor.
Study Results. Each Party shall designate a contact person to be primarily responsible for communicating with such person’s counterpart on all issues concerning the Initial Studies. Through such contact person, ViroPharma shall keep Schering reasonably informed on and involved in the progress of the Initial Studies, including by providing Schering with quarterly written status reports covering all of the Initial Studies. ViroPharma shall provide Schering with copies of all interim data and results generated from any of the Initial Studies, as well as all of the final data and results of each of the Initial Studies, including access to or copies of the database from each Interim Study in a format mutually agreeable to the Parties, promptly after they become available. All such data and results shall constitute Know-How, shall be treated as Confidential Information in accordance with Article 5, and shall only be used by Schering for the purpose of evaluating the Compound and the Product to determine whether or not to exercise the Option. The Parties acknowledge that the data and results from the Initial Studies are subject to disclosure to and use by Sanofi-Synthelabo as set forth in Section 3.3 of the SaSy Agreement.
Study Results. InNexus will provide to CORIXA reports of the results for each of the experiments or studies InNexus conducts as outlined in Exhibit B, such reports to be provided to CORIXA in a timely manner following the completion of each experiment or study. Any and all reports communicated to CORIXA by InNexus within the scope of this Agreement, may be freely used by CORIXA but only for its own internal purposes. CORIXA will provide to InNexus reports of the results for each of the experiments or studies CORIXA conducts as outlined in Exhibit B, such reports to be provided to InNexus in a timely manner following the completion of each experiment or study. Any and all reports communicated to InNexus by CORIXA within the scope of this Agreement, may be freely used by InNexus for its own internal purposes.
Study Results. 8.1 Upon completion of the Additional Reliability Study, issuance of the final invoice and payment by Requestor of any amount due pursuant to Section 7.3 of this Agreement, the NYISO and Transmission Owner will jointly deliver the results of the completed Additional Reliability Study to Requestor, and the Parties will meet at a mutually agreeable time and place to review the results of the Additional Reliability Study. The NYISO and Transmission Owner will also provide the results of the Additional Reliability Study to Requestor in electronic format.
8.2 The NYISO and Transmission Owner will review the results of the Additional Reliability Studies to determine whether the results reveal Confidential Information that may not be disclosed to the Requestor pursuant to the NYISO’s Code of Conduct or is otherwise identified by Transmission Owner as their own Confidential Information. Prior to the delivery to the Requestor of the study results, NYISO and Transmission Owner will remove or sufficiently mask all Confidential Information to avoid the disclosure of any Confidential Information to the Requestor. The NYISO and Transmission Owner will treat the Study Request and the results of the Additional Reliability Study as Confidential Information in accordance with Attachment F to the OATT. The NYISO will not include the results of the Additional Reliability Study in the Reliability Needs Assessment or Comprehensive Reliability Plan. Notwithstanding the foregoing, the Requestor acknowledges and agrees that the NYISO and Transmission Owner shall be free to provide appropriate response to the New York State Department of Public Services (NYSDPS) with regard to any requests for information they may submit to the NYISO or Transmission Owner regarding the generator or the study, the scope of work after the Requestor has been provided written notice of the NYSDPS’s request for information. In responding to such requests all Parties shall treat the study and the study results as confidential, commercial sensitive, proprietary information of the Requestor. The Requestor further acknowledges and agrees that the NYISO and Transmission Owner may disclose the results of this study, and that the NYISO may post the results of the Additional Reliability Study on its website, if and when Requestor seeks to obtain regulated cost recovery from an applicable state or federal regulatory authority based upon the results of the Additional Reliability Study or if the Requestor otherwis...
Study Results. The Majority Stockholder will have irrevocably assigned to Company all rights, title and interest in the Study Results to the extent within the Field and all inventions, improvements or discoveries made or reduced to practice in the performance of the Study to the extent within the Field (including all Intellectual Property therein). “Study Results” means all results, data, records, work product, laboratory notes and copies thereof and all Intellectual Property and Intellectual Property Rights therein, resulting from or connected with the experimental studies with syngeneic and humanized mice models (“Study”).
Study Results. The Facilities Study will document the necessary upgrades and associated costs in order to ensure the proposed DER will safely operate and not adversely affect other members when interconnected to the CEC system.
Study Results. All Sponsor information provided in connection with the Study, Sponsor protocols (in particular the Protocol) are and will remain the sole property of Sponsor. In addition, all data, results and other information derived from the Study, and all Records and documents, including, without limitation, all CRFs, study worksheets and laboratory data reports and other work product, created in the 5.1 Výsledky Studie. Veškeré údaje Zadavatele poskytnuté v souvislosti se Studií, protokoly (zejména Protokol) Zadavatele jsou a nadále zůstanou výhradním majetkem Zadavatele. Výhradním majetkem Zadavatele budou dále i veškeré údaje, výsledky a jiné informace zjištěné v rámci Studie a všechny Záznamy a dokumenty, zejména všechny Formuláře CRF, pracovní výkazy v rámci studie a zprávy s laboratorními údaji a další
